NEW YORK (GenomeWeb News) - Agendia said today that it has signed a license agreement with the Erasmus University Medical Center in Rotterdam, the Netherlands, giving it exclusive rights to a genetic profile that predicts resistance to tamoxifen.
 
Agendia said it will validate the tamoxifen profile in collaboration with the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.